Exploring the link between Parkinson’s disease and type 2 diabetes mellitus in *Drosophila*

Francisco José Sanz\(^1,2\) | Cristina Solana-Manrique\(^1,2\) | Joaquín Lilao-Garzón\(^3\) | Yeray Brito-Casillas\(^3\) | Silvia Muñoz-Descalzo\(^3\) | Nuria Paricio\(^1,2\) ©

\(^1\)Departamento de Genética, Facultad CC Biológicas, Universidad de Valencia, Burjassot, Spain
\(^2\)Instituto Universitario de Biotecnología y Biomedicina (BIOTECMED), Universidad de Valencia, Burjassot, Spain
\(^3\)Instituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS), Universidad de Las Palmas de Gran Canaria (ULP GC), Las Palmas de Gran Canaria, Spain

**Abstract**

Parkinson’s disease (PD) is the second most common neurodegenerative disease. Diabetes mellitus (DM) is a metabolic disease characterized by high levels of glucose in blood. Recent epidemiological studies have highlighted the link between both diseases; it is even considered that DM might be a risk factor for PD. To further investigate the likely relation of these diseases, we have used a *Drosophila* PD model based on inactivation of the *DJ-1β* gene (ortholog of human *DJ-1*), and diet-induced *Drosophila* and mouse type 2 DM (T2DM) models, together with human neuron-like cells. T2DM models were obtained by feeding flies with a high sugar-containing medium, and mice with a high fat diet. Our results showed that both fly models exhibit common phenotypes such as alterations in carbohydrate homeostasis, mitochondrial dysfunction or motor defects, among others. In addition, we demonstrated that T2DM might be a risk factor of developing PD since our diet-induced fly and mouse T2DM models present DA neuron dysfunction, a hallmark of PD. We also confirmed that neurodegeneration is caused by increased glucose levels, which has detrimental effects in human neuron-like cells by triggering apoptosis and leading to cell death. Besides, the observed phenotypes were exacerbated in *DJ-1β* mutants cultured in the high sugar medium, indicating that DJ-1 might have a role in carbohydrate homeostasis. Finally, we have confirmed that metformin, an antidiabetic drug, is a potential candidate for PD treatment and that it could prevent PD onset in T2DM model flies. This result supports antidiabetic compounds as promising PD therapeutics.

**Key words**

drosophila, high fat/sugar diet, mouse model, neurodegeneration, Parkinson’s disease, type 2 diabetes mellitus

**Abbreviations:** DA, dopaminergic; DM, diabetes mellitus; ER, endoplasmic reticulum; fPD, familial Parkinson’s disease; HFD, high fat diet; HSD, high sugar diet; ILP, insulin-like peptide; ISP, insulin signaling pathway; MET, metformin; ND, normal diet; OS, oxidative stress; PD, Parkinson’s disease; ROS, reactive oxygen species; sPD, sporadic Parkinson’s disease; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TCA, tricarboxylic acid; TH, tyrosine hydroxylase.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2022 The Authors. *The FASEB Journal* published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.
1 INTRODUCTION

Parkinson’s disease (PD) is the second most common neurodegenerative disease, and the first motor disorder affecting more than 1%–3% of the worldwide population over 60 years. Its major pathological hallmark is the selective loss of dopaminergic (DA) neurons in the substantia nigra pars compacta, which leads to PD-characteristic motor deficits. However, the exact cause of this neurodegeneration remains unknown. To date, multiple pathways appear to contribute to PD onset and progression, like accumulation of misfolded protein aggregates, mitochondrial dysfunction, oxidative stress (OS), neuroinflammation, endoplasmic reticulum (ER) stress, or genetic mutations. In addition, metabolic alterations have been recently shown to play an important role in PD physiopathology. Specifically, a possible link between glucose metabolism alterations and neurodegeneration has been demonstrated. Even though the majority of PD cases are sporadic (sPD), several genes responsible for familial PD forms (fPD) have been identified. Interestingly, the study of their functions has provided useful information to decipher several molecular mechanisms underlying PD. Among them, DJ-1, initially described as an oncogene, is a causative gene of early-onset fPD. However, further studies demonstrated that the DJ-1 protein have additional functions such as antioxidant, via free-radical scavenging and transcriptional regulation of antioxidant genes, as mitochondrial function modulator, deeglycase, redox-dependent molecular chaperone, and as a factor involved in proteolysis and metabolism.

Diabetes mellitus (DM) is a metabolic disease characterized by high levels of glucose in blood, due to a diminished insulin production or to the appearance of insulin resistance. There are, mainly, two types of DM: type 1 DM (T1DM) and type 2 DM (T2DM). T1DM is due to the autoimmune loss of pancreatic β-cells, whereas T2DM is caused by the appearance of insulin resistance and a progressive decrease of insulin production in β-cells. The genetics of T2DM is complex and not completely defined. In addition, its prevalence is growing worldwide and it accounts for the 90%–95% of the cases of DM. Interestingly, there is growing evidence that an important link between PD and T2DM does exist. In fact, T2DM and PD share characteristic phenotypes such as mitochondrial dysfunction, increased OS levels, inflammation and ER stress, which eventually might lead to the activation of the apoptotic pathway. Moreover, brain is one of the major targets of insulin; therefore, dysregulation of the insulin signaling pathway (ISP) may exert detrimental effects in neurons, and even be the cause of cell death. In addition, due to the common phenotypes found between both diseases, several antidiabetic drugs are being tested as potential PD treatments.

Animal models have become powerful tools to study and identify pathogenic mechanisms underlying human diseases like PD and DM. In this scenario, we work with a Drosophila PD model based on inactivation of the DJ-1β gene (ortholog of human DJ-1). Previous studies demonstrated that DJ-1β mutant flies displayed PD-related phenotypes like motor defects and reduced lifespan. Moreover, these flies showed alterations in the activity of enzymes involved in the defense against OS and, in consequence, increased OS marker levels such as several reactive oxygen species (ROS) and protein carboxylation. Furthermore, we have also shown that DJ-1β mutant flies display metabolic disturbances reflected by an increase in the glycolytic pathway and alterations in several metabolite levels. Drosophila has also emerged as an excellent model for DM since it uses triacylglycerols and glycogen to store energy like humans. In addition, Drosophila synthesizes insulin-like peptides (ILP), which are secreted by specialized neurons, named insulin-producing cells, and glia in the brain. There are seven ILPs that are partially redundant, however, ILP2, 3 and 5 are the most important considering glycemia control. Moreover, Drosophila regulates glucose homeostasis through the ISP, which is evolutionary conserved and contains similar elements and regulatory interactions than those found in human ISP. To date, several strategies have been developed to model T2DM in this organism. One involves feeding flies with an hypercaloric medium, in which sugar, protein, or lipid content is increased with respect to regular food; alternatively T2DM can be modeled by silencing several genes like those encoding ISP components, among others.

In this study, we have used PD and T2DM model flies, a mouse T2DM model and neuron-like human cells to identify links between both diseases. The Drosophila T2DM model is a diet-induced one in which wild-type flies were fed with high sugared medium; the mouse T2DM model is a well established one based on high-fat diet, which is the best one reflecting the human disease as it develops together with obesity. While in flies, simple sugars from food are taken up passively from the digestive tract, in mice the excess of energy from the hypercaloric diet is stored as fat, inducing obesity. Fat accumulation leads to insulin resistance, hyperglycemia, and ultimately T2DM. Our results showed that Drosophila PD and T2DM models exhibit common phenotypes like alterations in carbohydrate metabolism, mitochondrial dysfunction or motor defects, among others. In addition, we demonstrated that both fly and mouse T2DM models presented DA neuron dysfunction, a hallmark of PD. We have also confirmed that increased glucose levels have a detrimental effect in human neuron-like cells by triggering apoptosis, which leads to cell death. Besides, the hypercaloric medium used to
generate T2DM model flies exacerbated those phenotypes in DJ-1β mutants, indicating that DJ-1 might have a role in carbohydrate homeostasis. Finally, we have confirmed that metformin, an antidiabetic drug, is a potential candidate for PD treatment and that it could prevent PD onset in T2DM model flies.

2 | MATERIAL AND METHODS

2.1 | Fly stocks and culture conditions

Fly stocks employed in this study were y,w (Bloomington Drosophila Stock Center #6598; y,w<sup>118</sup>) and the DJ-1<sup>β</sup> strain (referred to as DJ-1β) from the J. Chung laboratory. Stocks and fly crosses were cultured using standard Drosophila medium at 25°C. Newly eclosed female flies were fed either with control medium (normal diet, ND) or with a high sugar medium (high sugar diet, HSD), prepared using standard Drosophila food supplemented with sucrose to a final concentration of 30%. Flies were transferred to new vials every 2–3 days. When performing metformin treatments, vials with either control or high sugar medium contained a final concentration of 25 mM of this compound (Sigma-Aldrich).

2.2 | Rotenone exposure

For rotenone treatment, 1-day-old y,w female flies were cultured in standard Drosophila feed supplemented with 500 μM rotenone for 7 days (rotenone was dissolved in DMSO and a stock of 100 mM was prepared). Flies were transferred to new vials every 2 days.

2.3 | Determination of glycogen and soluble carbohydrates

Glycogen and soluble carbohydrates were calculated using a protocol adapted from Ref. [36]. Briefly, groups of five 15-day-old female flies of each genotype and culture condition were homogenized in 200 μl of PBS with a steel bead using a TissaueLyser LT (Qiagen) for 2 min at 50 Hz. Fly extracts were further centrifuged at 180 g for 10 min at 4°C in order to discard debris. Next, 90 μl of the supernatant were collected, to which 10 μl of sodium sulfate 20% (w/v) and 750 μl of methanol were added. After vortexing the sample, it was centrifuged at 180 g for 15 min at 4°C. In this step, glycogen remained in the pellet and soluble carbohydrates in the supernatant. For glycogen estimation, pellet was washed twice with 80% methanol. Then, 1 ml of anthrone reagent (1.42 mg/ml in sulfuric acid 70% [v/v]) was added and samples were heated at 90°C for 15 min. Subsequently, samples were cooled on ice and centrifuged. About 200 μl of each replicate was added in a 96-well plate and absorbance was measured at 625 nm using an Infinite 200 PRO reader (Tecan). For soluble carbohydrates estimation, supernatant was evaporated until a volume of 20 μl remained, and 750 μl of anthrone reagent was next added. Samples were heated at 90°C for 15 min and, subsequently, cooled on ice. A volume of 200 μl of each sample was transferred to a 96-well plate, and absorbance was measured at 625 nm. In all experiments, three replicates per each culture condition were carried out.

2.4 | Weight estimation

Groups of ten 15-day-old flies of each genotype and culture condition were weighed in a microbalance to estimate their total weight. At least, six replicates per each group of flies were studied.

2.5 | Measurement of ATP levels

ATP levels were measured as described in Ref. [7] using the ATP Determination Kit (Invitrogen) following manufacturer’s instructions. Briefly, groups of five female flies were homogenized in 200 μl of reaction buffer (supplied by the commercial kit). Then, fly extracts were boiled 4 min and centrifuged at 18500 g for 10 min at 4°C in order to discard debris. Subsequently, 5 μl of fly extracts were added to 100 μl of the standard reaction solution in a white 96-well plate and luminescence was measured using an Infinite 200 PRO reader (Tecan). All experiments were performed in triplicate.

2.6 | RT-qPCR analyses

Total RNA from ten 15-day-old T2DM model or control female flies was extracted and reverse transcribed as described in Ref. [6]. RT-qPCR was performed as in Ref. [6], and the following pairs of primers were used: tubulin direct primer (5’-GATTACCGCCTCTCTGGAAGATCTCAG-3’); tubulin reverse primer (5’-ACCAGAGGGAAAGTGAAATACGTG-3’); PI3K direct primer (5’-ATTGGAATACGTGACATCACAGA-3’); PI3K reverse primer (5’-TCGTTTCTCTCTGCTGTAACAGA-3’); InR direct primer (5’-TTTCCAGGACATCGCTCAGAATCA-3’); InR reverse primer (5’-GACCTTAGCATAGCTCGG-3’); chico direct primer (5’-TATGCACAACACGATACTGAG-3’); chico reverse primer (5’-GACTCTGTGTTCTCGCAACA-3’). tubulin levels were measured and used as an internal
control for RNA amount in each sample. All experiments were performed in quadruplicate.

2.7 | Climbing assays

Motor performance of flies was analyzed by carrying out a climbing assay as previously described in Ref. [37]. Briefly, groups of 10–20 female flies were transferred to graduated plastic tubes, acclimated for 1 min, gently tapped down to the tube bottom, and allowed to climb for 10 s. At least four groups of each condition were analyzed and the climbing ability was measured as the average height reached by each group after 10 s.

2.8 | T2DM mouse model

Mouse work was conducted in accordance with National and European requirements (RD 1201/2005, Law 32/2007, EU Directive 2010/63/EU) and was approved by the animal ethics research committee (re-used animals from protocol OEA-ULPGC 10/2019R1) from the University of Las Palmas de Gran Canaria.

Brains from 10-month-old C57BL/6J female mice randomly assigned to be fed with either standard diet (ND) (Envigo, Global Diet 2014) or high fat diet (HFD) (60% energy from fat, D12492; Research Diets, New Brunswick, NJ) for 12 weeks were snap-frozen in liquid nitrogen and stored at −80°C. Brains were thawed and dissected to obtain the Caudate-Putamen region. 100 mg samples were homogenized in 1 ml of RIPA buffer supplemented with a protease inhibitor cocktail (PPC1010, Sigma-Aldrich) with an Ultra-Turrax T25 device. Then, lysates were sonicated (Bioruptor® Standard, Diagenode) on ice for 20 min in 30 s pulses and centrifuged 10,000 g for 20 min.

2.9 | Cell culture and metformin treatment

DJ-1-deficient and pLKO.1 control SH-SY5Y cells previously generated by our laboratory [37] were cultured in selective growth medium consisting of Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12) (Biowest) supplemented with 10% (v/v) fetal bovine serum (Capricorn), 1% non-essential amino acids, and 100 mg/ml penicillin/streptomycin (Labclinics) at 37°C and 5% CO₂. Cell viability after supplementation with different concentrations of glucose or MET was evaluated using an MTT (3-[4, 5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay, as previously described in Ref. [6].

2.10 | Quantification of protein carbonyl group formation

Protein carbonylation levels were measured in 15-day-old flies cultured in ND and HSD containing 0.1% DMSO for untreated control experiments or supplemented with a final concentration of 25 mM metformin for treatment experiments. Protein carbonyl groups were measured in fly extracts using 2,4-dinitrophenyl hydrazine derivatization in 96-well plates (Greiner 96-well plate, polypropylene) as previously described in Ref. [6]. All experiments were carried out using three biological replicates and three technical replicates for each sample.

2.11 | Western blotting

Western blots were performed as described in Ref. [6]. Protein extraction of flies fed with either ND or HSD, and supplemented with either 25 mM MET or 0.1% DMSO as control, was adapted from Ref. [6]. Briefly, fifty 28-day-old fly heads were homogenized in 200 μl of 50 mM Tris–HCl, pH 7.4, with a steel bead in a TissueLyser LT (Qiagen) for 3 min at 50 Hz. Fly extracts were centrifuged at 14,500 g for 10 min at 4°C and supernatant was collected. Protein extraction of pLKO.1 SH-SY5Y cells treated with 125 μM of glucose or control medium was carried out as previously described in Ref. [6]. Protein extraction of mouse brain was carried out as commented above (see T2DM mouse model section). The primary antibodies used were anti-TH (1:1000, Sigma), anti-α-tubulin (1:5000; Hybridoma Bank; 12G10), anti-JNK, anti-phospho-JNK (Thr183/Tyr185) (1:1000, Cell Signaling), and β-actin (1:1000, Santa Cruz). Secondary antibodies used were anti-rabbit or anti-mouse HRP-conjugated (1:5000, Sigma). Quantifications of protein levels were performed with an ImageQuant™ LAS 4000mini Biomolecular Imager (GE Healthcare), and images were analyzed with ImageJ software (NIH).

2.12 | Enzymatic assays

The enzymatic activities of phosphofructokinase (Pfk; EC 2.7.1.11), pyruvate kinase (Pk; EC 2.7.1.40), and hexokinase (Hk; EC 2.7.1.1) were measured using coupled enzymatic assays in extracts of 15-day-old flies fed with either ND or HSD, as previously described in Ref. [6]. All experiments were performed in triplicate.

2.13 | Statistical analyses

The significance of differences between means was assessed using a t-test when two experimental groups were
analyzed. In experiments in which more than two experimental groups were used, the statistical analysis was made using the ANOVA test and Tukey’s post-hoc test. Differences were considered significant when \( p < .05 \). Data are expressed as means ± standard deviation (SD).

### 3 | RESULTS

#### 3.1 | DJ-1β mutant and rotenone-treated flies exhibit alterations in carbohydrate levels

Although the cause of PD is still unknown, several studies suggest that metabolic alterations might play an important role in developing the disease. Indeed, we have recently demonstrated that DJ-1β mutant flies displayed an increased glycolytic rate as well as changes in the levels of several metabolites when compared with controls. Among them, we found an important increase in trehalose levels, which is the main circulating sugar in the *Drosophila* hemolymph. To detect additional alterations in carbohydrate levels, we decided to quantify soluble carbohydrates and glycogen in our fPD model flies. Our results showed that 15-day-old DJ-1β mutants have increased levels of both (Figure 1A,B). Interestingly, we found that 15-day-old DJ-1β mutants also exhibited reduced weight compared with control flies (Figure 1C).

Weight loss is often associated with an increase of energy expenditure, which could be explained by a switch from tricarboxylic acid (TCA) cycle to glycolysis. In fact, recent studies from our group have confirmed this switch, since fPD model flies showed increased glycolytic rate and reduced activity of several enzymes of the TCA cycle. Subsequently, we analyzed whether rotenone-treated flies, a well-established *Drosophila* sPD model showed similar phenotypes to DJ-1β mutants. Indeed, we found that these flies also exhibited changes in carbohydrate metabolism when compared with vehicle-treated flies (DMSO), reflected by increased soluble carbohydrates and glycogen levels (Figure 1D,E). In addition, rotenone-treated flies showed reduced weight (Figure 1F). Taken together, our results indicated that both fPD and sPD model flies displayed alterations in carbohydrate metabolism.

#### 3.2 | T2DM model flies display alterations in carbohydrate metabolism

High blood glucose level is a T2DM hallmark. Excitingly, several studies have revealed the existence of an association between T2DM and PD. While epidemiological links between both diseases have been deeply described, the underlying pathways and common mechanisms remain still unresolved. In such a scenario, we decided to investigate the molecular and phenotypic links between T2DM and PD in *Drosophila*. Several *Drosophila* models for human T2DM have been described. Among them, we used a diet-induced T2DM model in which wild-type flies were fed with a medium containing six times more sugar (HSD) than control medium (ND). A previous report showed that those flies developed insulin resistance, which is a hallmark of T2DM. To determine whether HSD-fed adult flies exhibited T2DM-related phenotypes we first measured carbohydrate levels. Our results indicated that 15-day-old T2DM model flies displayed increased soluble carbohydrates and glycogen levels (Figure 2A,B). Subsequently, we found that these

---

**FIGURE 1** Metabolic alterations in PD model flies. (A,B) Soluble carbohydrate and glycogen levels in 15-day-old DJ-1β-mutant flies were analyzed using the anthrone method by absorbance. (C) Fly weight of 15-day-old DJ-1β mutant flies. (D,E) Soluble carbohydrate and glycogen levels in 15-day-old rotenone-treated flies were analyzed using the anthrone method by absorbance. (F) Fly weight of 15-day-old rotenone-treated flies. Results were normalized to data obtained in y,w control flies in A–C; and to data obtained in flies cultured in control medium (DMSO) in D–F. Error bars show SD from three replicates and three independent experiments in A, B, D, and E; and from at least six independent experiments in C and F (\( *p < .05; **p < .01; ***p < .001 \)).
flies presented increased expression of ILP2, a gene encoding one of the three ILPs related to glycemia control\(^7\) (Figure 2C), thus confirming the existence of insulin resistance.\(^{28}\) In addition, we analyzed the expression of three genes encoding ISP components like InR, PI3K, and chico. Our results showed that T2DM model flies exhibited increased expression of those genes (Figure 2D), indicative of pathway activity reduction.\(^{28}\) Taken together, increased levels of carbohydrates, the presence of insulin resistance, and decreased ISP activity validated flies fed with a HSD as a Drosophila T2DM model.

### 3.3 T2DM and PD model flies present common phenotypes

As indicated above, multiple studies highlight the link between PD and T2DM. Indeed, both diseases exhibit common phenotypes such as mitochondrial dysfunction.\(^{14}\) To confirm this relation in our Drosophila models, we aimed to test whether T2DM model flies could present phenotypes similar to those observed in DJ-1\(^{β}\) mutants. Mitochondria are the main ROS producers, and their dysfunction leads to increased OS levels.\(^{24}\) In fact, previous studies showed that DJ-1\(^{β}\) mutant flies displayed elevated OS levels as well as alterations in antioxidant enzymes.\(^{25,26}\) Hence, we decided to study OS levels in wild-type HSD-fed flies compared with controls (ND-fed flies). Our results demonstrated that 15-day-old T2DM model flies showed an increase in protein carbonylation levels (an OS marker) (Figure 3A). In addition, it has been recently reported that mitochondrial alterations in DJ-1\(^{β}\) mutant flies led to a reduction of ATP levels.\(^7\) Consequently, glycolysis was enhanced in PD model flies in order to counteract the loss of energy production.\(^{6,45}\) Likewise, we have found that 15-day-old T2DM model flies presented a reduction of ATP levels (Figure 3B), probably due to mitochondrial dysfunction. In addition, increased activity of hexokinase (Hk), phosphofructokinase (Pfk), and pyruvate kinase (Pk), enzymes involved in key regulatory steps of the glycolysis, was observed in these flies (Figure 3C), suggesting an increased glycolytic rate. Moreover, we also found that T2DM flies presented reduced weight (Figure 3D), likely due to an enhanced glycolytic activity as suggested for DJ-1\(^{β}\) mutants. In relation with this, it has been found that other invertebrate T2DM models also presented decreased weight, which was associated with a reduction of food intake; however, the total amount of calories ingested by T2DM model animals was higher than that by controls. Therefore, it was suggested that weight loss might be caused by alterations in the mechanisms implicated in tissue growth.\(^{28,46}\)

On the other hand, T2DM is also considered as a risk factor of developing PD.\(^{14}\) Among the most typical PD-related phenotypes exhibited by DJ-1\(^{β}\) mutant flies, we found locomotor alterations and reduced life span.\(^{25,26}\) In order to determine if T2DM might trigger PD onset, we decided to study these phenotypes in wild-type HSD-fed flies compared with controls (ND-fed flies). Our results demonstrated that 15-day-old T2DM model flies have a reduced life span (Figure 4A). Besides, we found that flies fed with a HSD displayed locomotor deficits at 28 days of age, although no defects were found in younger flies (Figure 4B). It was reported that motor symptoms appear in PD when there is approximately 50%–60% of DA neuron loss.\(^{47}\) Therefore, we decided to quantify levels of tyrosine hydroxylase (TH), a DA neurons marker, in T2DM model flies brain extracts to monitor DA neuron alterations. For doing so, we performed western-blot analysis with 28-day-old T2DM model flies heads with an anti-TH antibody. Interestingly, previous works have demonstrated that several PD models are able to develop PD-related phenotypes without exhibiting DA neurons loss. The presence of DA neuron disturbances was confirmed in those models, hence suggesting that these phenotypes might be probably appearing by alterations in DA neurons function.\(^{48–50}\) However, another study reported that DA neuron content in fly brains is related to TH levels.\(^{51}\) Our results showed that TH levels were, in fact, reduced in 28-day-old T2DM model flies (Figures 4C and S1); hence, suggesting DA neuron loss or dysfunction in these flies. Taken together, our results validated the link between PD and T2DM in Drosophila models and supported PD development in T2DM.

### 3.4 DJ-1-deficiency leads to alterations in carbohydrate homeostasis

Several studies have demonstrated that modeling T2DM with HSD-fed animals resulted in increased OS levels, likely caused by high glucose concentration.\(^{52}\) Interestingly, besides the already known antioxidant effect of the DJ-1 protein, there is growing evidence that it might also play an important role in metabolism.\(^7,53\) Therefore, it is plausible that loss of DJ-1 function could be detrimental under hyperglycemic conditions. To confirm this, DJ-1\(^{β}\) mutant flies were fed with a HSD during 15 days. Our results showed that they presented increased soluble carbohydrates as well as glycogen levels (Figure 5A,B). To determine whether DJ-1\(^{β}\) could play a significant role in their homeostasis, we studied if the increase of soluble carbohydrate and glycogen levels was affected by the HSD compared with ND (HSD/ND) in PD model and control flies. Our results showed that the increase of glycogen levels in HSD/ND was higher in DJ-1\(^{β}\) mutant flies than in controls, while no differences
were found in the increase of soluble carbohydrates (Figure 5C,D). This suggests that DJ-1β may play an important role in glycogen metabolism. It has been reported that hyperglycemia increases OS levels. Since DJ-1β mutants were shown to be hypersensitive to OS conditions (induced by paraquat, rotenone, H2O2, etc.), we analyzed if feeding PD model flies with a HSD had detrimental effects on motor ability. Accordingly, DJ-1β mutant flies cultured in those conditions displayed motor defects from day 7 (Figure 5E), while controls fed with the same diet showed reduced motor ability at day 28 (Figure 4B). These results confirm that DJ-1β mutant flies are more sensitive to increased carbohydrate levels, supporting an important role of DJ-1β in carbohydrate metabolism.

### 3.5 High glucose levels trigger neurodegeneration in mice and SH-SY5Y human cells

To further study the relevance of T2DM on PD development, we decided to use a T2DM mouse model. We used a well-established mouse T2DM model induced by 12 weeks of HFD which leads to high blood glucose levels. As in the T2DM model flies, we found that 10-month-old female mice fed with HFD showed a TH expression reduction in brains when compared with ND-fed mice (Figures 6 and S2). These results supported the onset of PD in these mice. Similar results have been obtained in other T2DM mouse models.

To date, the cause by which T2DM might be triggering PD development remains unclear. The potential causes...
described are vascular defects, increased levels of methylglyoxal, OS, or glucose. Since antidiabetic drugs (compounds able to reduce glucose levels) are being found as potential PD treatments, we aimed to study if elevated glucose levels might be detrimental for neuron-like SH-SY5Y cells. To do this, we treated these cells with increased glucose concentrations in a range of 50–175 mM and subsequently performed MTT viability assays. Our results indicated that viability was significantly reduced 100 mM glucose onwards (Figure 7A), hence confirming the toxic effect of high glucose levels in these cells. Subsequently, to study the molecular mechanism by which glucose might be producing cell death, we decided to measure the activation of the pro-apoptotic factor JNK after glucose treatment. We found that cells treated with 125 mM glucose showed increased JNK phosphorylation levels when compared with cells treated with vehicle (Figures 7B and S3), which ultimately leads to cell death. Together, results obtained in the T2DM mouse model and in neuron-like SH-SY5Y humans cells supported the relevance of high sugar levels in neuronal degeneration.

### 3.6 Metformin ameliorates phenotypes in DJ-1-deficient human cells and T2DM model flies

Given the growing evidence of the relationship between PD and T2DM, antidiabetic drugs are being considered as promising PD therapies. Interestingly, a pilot screen
carried out by our group in DJ-1β mutant flies identified metformin as a candidate therapeutic compound for PD, being able to suppress motor defects in PD model flies. Metformin (MET) is a well-known antidiabetic drug. However, it has been also reported to exert a neuroprotective effect through the 5′-adenosine mono-phosphate-activated protein kinase (AMPK) signaling pathway. Therefore, we aimed to confirm this compound efficiency as PD therapeutic. First, we decided to determine whether MET was able to affect viability of our cell PD model based on DJ-1 deficiency. We found that MET increased viability in DJ-1-deficient SH-SY5Y cells in a dose-dependent manner, being 50 μM the most effective concentration (Figure S4). Subsequently, we tested if this compound was able to suppress DM as well as PD phenotypes in T2DM model flies. We found that HSD-fed flies treated with MET presented reduced levels of soluble carbohydrates and glycogen when compared with flies treated with DMSO as vehicle (Figure 8A,B), hence confirming its antidiabetic activity. Subsequently, we also demonstrated that MET was able to suppress typical PD phenotypes, by reducing protein carbonylation levels (Figure 8C), and improving locomotor activity of these flies (Figure 8D). Accordingly, MET also increased TH expression in T2DM model flies (Figures 8E and S1), which correlates with a reduction of DA neurodegeneration. These results confirm that MET might be a promising candidate therapeutic for PD.

4 DISCUSSION

The increase in life expectancy is leading to an increase in age-associated diseases, like PD and DM, causing important social as well as economic burdens. PD prevalence increases with age and affects 1%–3% of the population over 60 years.1 As for DM, it has a prevalence of 8.8% in the group of population between 20 and 79 years in 2017.64 In addition, an increase in the number of cases of both diseases is expected in the future.63,64 Interestingly,
recent epidemiological studies suggest that T2DM and PD are probably related. In particular, most of them demonstrated that T2DM is a risk factor of developing PD and could worsen cognition in PD patients. Accordingly, an increase in ISP activity was reported to improve motor and cognitive abilities, and to exert neuroprotective effects in PD patients. Besides, alterations found in chronic T2DM patients, like microvascular complications, may lead to nephropathy, retinopathy, and neuropathy. However, it was also proposed that neuropathy might be produced in T2DM by other mechanisms, such as hyperglycemia. Regarding this, we recently showed that DJ-1β mutant flies presented higher levels of trehalose, the main circulating sugar in the Drosophila hemolymph. Accordingly, we demonstrated in this work that these flies also presented higher levels of soluble carbohydrates as well as glycogen. Additionally, we also confirmed that T2DM flies showed a reduction of ISP activity and an increase of ILP2 expression, which along with the increase of carbohydrate levels are hallmarks of T2DM. Our results also showed that HSD-fed flies were smaller than those fed with ND, which could be explained by an increase of energy expenditure caused by the switch of metabolism from TCA to glycolysis. This assumption was confirmed by finding increased activity of key enzymes of the glycolytic pathway in such flies. Moreover, mitochondrial defects have been reported in T2DM models, which suggests a reduction in TCA activity. Excitingly, this work confirmed that ATP levels were also reduced in T2DM model flies. The finding of common phenotypes in T2DM model flies and DJ-1β mutants clearly supports the relationship between both diseases. Many studies have been recently performed to evaluate the link between PD and T2DM. In fact, most of the epidemiological studies conclude that there is an important risk of developing PD in T2DM patients, although there are also contradictory results. It was also reported that hyperglycemia increases OS levels and promotes proteins glycation, which leads to their aggregation. Moreover, it has been shown that insulin plays an important role in the central nervous system, since neurons use glucose as the main energy substrate, acts as a pro-survival factor, and regulates mitochondrial homeostasis. Overall, these results support that T2DM is a risk factor of developing PD. Here, we have
confirmed that T2DM model flies exhibited PD-related phenotypes like reduced lifespan, locomotor defects but also DA neuron disturbances (inferred by reduced TH levels), which is a pathological hallmark of PD. According to our results in Drosophila, we have also shown that alterations in DA neurons are evident in a T2DM mouse model. Interestingly, DA neurodegeneration as well as motor defects has been reported in other T2DM animal models, hence supporting our findings. Several mechanisms have been proposed to explain neurodegeneration like vascular defects, increased methylglyoxal levels, OS or increased glucose levels. However, it was demonstrated that viability in SH-SY5Y neuroblastoma cell was impaired by high glucose levels (as previously reported in Ref. [58]), which triggered the apoptotic pathway by promoting JNK phosphorylation. Therefore, our results confirm that elevated glucose levels play a detrimental role in neuronal survival.

DJ-1 is a multifunctional protein, mainly acting as antioxidant. However, it also plays important roles in metabolism and mitochondrial homeostasis. In mammals, insulin is produced in pancreatic β-cells, which are hypersensitive to OS since they express reduced levels of antioxidant proteins. Besides, mitochondrial integrity and functionality preserves β-cells function and insulin secretion. Interestingly, it was shown that DJ-1 is upregulated under hyperglycemic conditions, and that DJ-1 levels are reduced in pancreatic islets of T2DM patients. Therefore, DJ-1 might play an important role in maintaining pancreatic β-cells homeostasis. In Drosophila, insulin is produced and secreted by specialized neurons, known as insulin-producing cells. Therefore, it would be interesting to determine if those Drosophila cells present similar characteristics than human pancreatic β-cells, and if DJ-1/β plays an important role in their homeostasis. Since hyperglycemic conditions might result in an increase of OS levels, PD models based on DJ-1 deficiency could be more sensitive to those conditions. In fact, it was reported that DJ-1-deficient mice showed glucose intolerance and reduced β-cell area, and were more sensitive to streptozotocin treatment, a chemical that induces inflammatory β-cells stress and leads to cell death. In the present study, we have found that DJ-1/β mutant flies fed with a HSD presented increased levels of soluble carbohydrates and glycogen as well as motor defects at an earlier age than those fed with ND. We have also shown that the increase of glycogen levels was higher in PD model than in control flies when fed with a HSD, thus suggesting that loss of DJ-1 function might produce alterations in glycogen metabolism. In fact, it was shown that hyperglycemia enhances the expression of genes involved in glycogen synthesis, such as glycogen synthase, and that glycogen levels can be related to alterations in β-cell metabolism.

Since T2DM and PD exhibit common phenotypes such as mitochondrial alterations, increased levels of OS markers, neuroinflammation as well as ER stress, compounds addressed to restore these phenotypes might be useful for treating both diseases. In fact, antidiabetic drugs such as PPAR (peroxisome proliferator-activated receptor) agonists, GLP-1 (glucagon-like peptide-1) receptor agonists, and MET are being considered as promising drugs for treating PD. In addition, there are several clinical trials to repurpose antidiabetic drugs in PD patients. Besides, a recent study has indicated that T2DM patients treated with antidiabetic drugs showed reduced PD incidence. Excitingly, a pilot screening assay carried out by our group identified MET as a compound able to improve motor performance in DJ-1/β mutant flies. Furthermore, it has been shown that MET also prevents cell death in another mouse model for T2DM. In this work, we have validated MET as a candidate compound for PD by confirming its effectiveness increasing viability in DJ-1-deficient cells. Besides, we have shown that MET is also able to suppress DM and PD-related phenotypes in T2DM flies. First, we have demonstrated that 15-day-old T2DM flies treated with MET showed reduced levels of soluble carbohydrates as well as glycogen, hence confirming its antidiabetic effect. Subsequently, we have shown that MET is able to reduce protein carbonylation in 15-day-old T2DM model flies to improve motor performance and to reduce DA neurodegeneration in 28-day-old T2DM flies. Additional studies have highlighted the neuroprotective effects of MET. For example, it was reported that MET increased cell viability through the activation of the AMPK pathway, as well as promoted autophagy and reduced microglial activation in a MPTP mouse PD model. Besides, it has been recently found that MET was able to reduce mitochondrial hyperactivity, an alteration that leads to neurodegeneration in a C. elegans PD model.

In summary, we have used DJ-1/β mutant flies, well-established Drosophila and mouse T2DM models, and neuron-like human cells to investigate the link between PD and T2DM. Our results demonstrated that fly models exhibit common phenotypes such as carbohydrate levels alterations, dysfunction in metabolic pathways related to energy production, and increased OS levels. In addition, we have shown that T2DM model flies develop PD-related symptoms with age, and that hyperglycemia might be one of the causes that triggers DA neurodegeneration in T2DM, both in fly and mammalian models. Interestingly, our results showed that MET, an antidiabetic drug, suppressed PD-related phenotypes
in T2DM model flies. Besides, it also enhances cell viability in \textit{DJ-1}-deficient human cells, thus supporting its use as a candidate PD therapeutic. Taken together, our results demonstrate the link between both diseases, and validate antidiabetic drugs as potential PD treatments. Finally, we have confirmed that \textit{DJ-1β} mutant flies are more vulnerable to hyperglycemic conditions. Therefore, we propose that loss of \textit{DJ-1} function could exert a detrimental effect in T2DM, being able to accelerate PD development in T2DM patients. Further experiments will be required to confirm this hypothesis.

**AUTHOR CONTRIBUTIONS**
Nuria Paricio, Silvia Muñoz-Descalzo, and Francisco José Sanz conceived and designed the research; Francisco José Sanz, Cristina Solana-Manrique, Joaquín Lilao-Garzón, and Yeray Brito-Casillas performed the research and acquired the data; Francisco José Sanz, Cristina Solana-Manrique, and Joaquín Lilao-Garzón analyzed and interpreted the data. All authors were involved in drafting and revising the manuscript.

**ACKNOWLEDGMENTS**
We are grateful to Dr. Jongkyeong Chung and the Bloomington Drosophila Stock Center for providing fly stocks. Research at the NP lab is supported by the University of Valencia (Programa de Acciones Especiales de Investigación, UV-INV-AE-1553209). SMD is supported by the “Viera y Clavijo” Program from the Agencia Canaria de Investigación, Innovación y Sociedad de la Información (ACIISI), and the ULPGC predoctoral program. Research at the SMD lab is supported by the ACIISI (CEI2019-02), Programa de Ayudas a la Investigación de la ULPGC, and ACIISI co-funded by FEDER Funds (ProID2020010013). Open access funding enabled and organized by ProjektDEAL.

**DISCLOSURES**
The authors declare no conflicts of interest.

**DATA AVAILABILITY STATEMENT**
The data that support the findings of this study are available on request from the corresponding author.

**ORCID**
Nuria Paricio https://orcid.org/0000-0001-7193-2532

**REFERENCES**
1. Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. \textit{J Neural Transm}. 2017;124(8):901-905.
2. Xiong Y, Yu J. Modeling Parkinson’s disease in drosophila: what have we learned for dominant traits? \textit{Front Neurol}. 2018;9:228.
3. Athauda D, Foltynie T. Challenges in detecting disease modification in Parkinson’s disease clinical trials. \textit{Parkinsonism Relat Disord}. 2016;32:1-11.
4. Anandhan A, Jacome MS, Lei S, et al. Metabolic dysfunction in Parkinson’s disease: bioenergetics, redox homeostasis and central carbon metabolism. \textit{Brain Res Bull}. 2017;133:12-30.
5. Maiti P, Manna J, Dunbar GL, Maiti P, Dunbar GL. Current understanding of the molecular mechanisms in Parkinson’s disease: targets for potential treatments. \textit{Transl Neurodegener}. 2017;6(1):28.
6. Solana-Manrique C, Sanz FJ, Ripollés E, et al. Enhanced activity of glycolytic enzymes in drosophila and human cell models of Parkinson’s disease based on \textit{DJ-1} deficiency. \textit{Free Radic Biol Med}. 2020;158:137-148.
7. Solana-Manrique C, Sanz FJ, Torregrosa I, et al. Metabolic alterations in a drosophila model of Parkinson’s disease based on \textit{DJ-1} deficiency. \textit{Cell}. 2022;11:331.
8. Sonninen TM, Hämmäläinen RH, Koskuvi M, et al. Metabolic alterations in Parkinson’s disease astrocytes. \textit{Sci Rep}. 2020;10(1):14474.
9. Bandres-Ciga S, Diez-Fairen M, Kim JJ, Singleton AB. Genetics of Parkinson disease: an introspection of its journey towards precision medicine. \textit{Neurobiol Dis}. 2020;137:104782.
10. Chai C, Lim KL. Genetic insights into sporadic Parkinson’s disease pathogenesis. \textit{Curr Genomics}. 2013;14(8):486-501.
11. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the \textit{DJ-1} gene associated with autosomal recessive early-onset Parkinsonism. \textit{Science}. 2003;299(5604):256-259.
12. Strobbe D, Robinson AA, Harvey K, Rossi L, et al. Distinct mechanisms of pathogenic DJ-1 mutations in mitochondrial quality control. \textit{Front Mol Neurosci}. 2018;11:68.
13. American Diabetes Association. Diagnosis and classification of diabetes mellitus. \textit{Diabetes Care}. 2013;36(suppl 1):S67-S74.
14. Hassan A, Kandel RS, Mishra R, Gautam J, Alaref A, Jahan N. Diabetes mellitus and Parkinson’s disease: shared pathophysiological links and possible therapeutic implications. \textit{Cureus}. 2020;12(8):e9853.
15. Khan MAB, Hashim MJ, King JK, et al. Epidemiology of type 2 diabetes—global burden of disease and forecasted trends. \textit{J Epidemiol Glob Health}. 2020;10(1):107-111.
16. Fiory F, Perruolo G, Cimmino I, et al. The relevance of insulin action in the dopaminergic system. \textit{Front Neurosci}. 2019;13:868.
17. Sharma T, Kaur D, Grewal AK, Singh TG. Therapies modulating insulin resistance in Parkinson’s disease: a cross talk. \textit{Neurosci Lett}. 2021;749:135754.
18. Rocha KMA, da Silva Goulart A, Costa MT, Salgueiro ACF, Folmer V. The role of type 2 diabetes mellitus as a risk factor for Alzheimer’s and Parkinson’s diseases. \textit{Res Soc Dev}. 2021;10(1):e2341011673.
19. Hong CT, Chen KY, Wang W, et al. Insulin resistance promotes Parkinson’s disease through aberrant expression of α-synuclein, mitochondrial dysfunction, and deregulation of the polo-like kinase 2 signaling. \textit{Cell}. 2020;9(3):740.
20. Renaud J, Bassareo V, Beaulieu J, et al. Dopaminergic neurodegeneration in a rat model of long-term hyperglycemia: preferential degeneration of the nigrostriatal motor pathway. \textit{Neurobiol Aging}. 2018;69:117-128.
21. Lilao-Garzón J, Valverde-Tercedor C, Muñoz-Descalzo S, Brito-Casillas Y, Wängner AM. In vivo and in vitro
models of diabetes: a focus on pregnancy. *Adv Exp Med Biol.* 2021;1307:553-576.

22. McGurk L, Berson A, Bonini NM. Drosophila as an in vivo model for human neurodegenerative disease. *Genetics.* 2015;201(2):377-402.

23. Muñoz-Soriano V, Paricio N. Drosophila models of Parkinson’s disease: discovering relevant pathways and novel therapeutic strategies. *Parkinsons Dis.* 2011;2011:520640.

24. Casani S, Gómez-Pastor R, Matallana E, Paricio N. Antioxidant compound supplementation prevents oxidative damage in a drosophila model of Parkinson’s disease. *Free Radic Biol Med.* 2013;61:151-160.

25. Lavara-Culebras E, Muñoz-Soriano V, Gómez-Pastor R, Matallana E, Paricio N. Effects of pharmacological agents on the lifespan phenotype of drosophila DJ-1β mutants. *Gene.* 2010;462(1-2):26-33.

26. Lavara-Culebras E, Paricio N. Drosophila DJ-1 mutants are sensitive to oxidative stress and show reduced lifespan and motor deficits. *Gene.* 2007;400(1-2):158-165.

27. Álvarez-Rendón JP, Salceda R, Riesgo-Escovar JR. Drosophila melanogaster as a model for diabetes type 2 progression. *Biomed Res Int.* 2018;2018:1417528.

28. Pasco MY, Léopold P. High sugar-induced insulin resistance in drosophila relies on the lipocalin neural Lazarillo. *PLoS ONE.* 2012;7(5):e36583.

29. Gáliková M, Klepsatel P. Obesity and aging in the drosophila model. *Int J Mol Sci.* 2018;19(7):1896.

30. Teleman AA, Ratzenböck I, Oldham S. Drosophila: a model for understanding obesity and diabetic complications. *Exp Clin Endocrinol Diabetes.* 2012;120(4):184-185.

31. Ligouri F, Mascolo E, Vernì F. The genetics of diabetes: what we can learn from drosophila. *Int J Mol Sci.* 2021;22(20):11295.

32. Morris SNS, Coogan C, Chameseddin K, et al. Development of diet-induced insulin resistance in adult *Drosophila melanogaster*. *Biochim Biophys Acta.* 2012;1822(8):1230-1237.

33. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN. Diet-induced type II diabetes in C57BL/6J mice. *Diabetes.* 1988;37(9):1163-1167.

34. Graham P, Pick L. Drosophila as a model for diabetes and diseases of insulin resistance. *Curr Top Dev Biol.* 2017;121:397-419.

35. Park J, Sung YK, Cha GH, Sung BL, Kim S, Chung J. Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction. *Gene.* 2005;361(1-2):133-139.

36. Foray V, Pelisson PF, Bel-Venner MC, et al. A handbook for uncovering the complete energetic budget in insects: the van Handel’s method (1985) revisited. *Physiol Entomol.* 2012;37(3):295-302.

37. Sanz FJ, Solana-Manrique C, Muñoz-Soriano V, Calap-Quintana P, Moltó MD, Paricio N. Identification of potential therapeutic compounds for Parkinson’s disease using drosophila and human cell models. *Free Radic Biol Med.* 2017;108:683-691.

38. Yasugi T, Yamasaki T, Nishimura T. Adaptation to dietary conditions by trehalose metabolism in drosophila. *Sci Rep.* 2017;7(1):1619.

39. Liesa M, Shirihai OS. Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. *Cell Metab.* 2013;17(4):491-506.

40. Wu R, Liu X-M, Su J-G, et al. DJ-1 maintains energy and glucose homeostasis by regulating the function of brown adipose tissue. *Cell Discov.* 2017;3:16054.
58. Cho SJ, Kang KA, Piao MJ, et al. 7,8-dihydroxyflavone protects high glucose-damaged neuronal cells against oxidative stress. *Biomol Ther*. 2019;27(1):85-91.

59. Ambacher KK, Pitzul KB, Karajgikar M, Hamilton A, Ferguson SS, Cregan SP. The JNK- and AKT/GSK3β- signaling pathways converge to regulate puma induction and neuronal apoptosis induced by trophic factor deprivation. *PLoS ONE*. 2012;7(10):e46885.

60. Sanz FJ, Solana-Manrique C, Torres J, Masía E, Vicent MJ, Paricio N. A high-throughput chemical screen in DJ-1β mutant flies identifies Zaprinast as a potential Parkinson’s disease treatment. *Neurotherapeutics*. 2021;2021(1):1-14.

61. Zhang XL, Wang ZZ, Shao QH, et al. RNAi-mediated knockdown of DJ-1 leads to mitochondrial dysfunction via Akt/GSK-3β and JNK signaling pathways in dopaminergic neuron-like cells. *Brain Res Bull*. 2019;146:228-236.

62. Paudel YN, Angelopoulou E, Piperi C, Shaikh MF, Othman I. Emerging neuroprotective effect of metformin in Parkinson’s disease: a molecular crosstalk. *Pharmacol Res*. 2020;152:104593.

63. Afentou N, Jarl J, Gerdhatham UG, Saha S. Economic evaluation of interventions in Parkinson’s disease: a systematic literature review. *Mov Dis Clin Pract*. 2019;6(4):282-290.

64. Standl E, Khunti K, Hansen TB, Schnell O. The global epidemics of diabetes in the 21st century: current situation and perspectives. *Eur J Prev Cardiol*. 2019;26(suppl 2):7-14.

65. Birse RT, Choi J, Reardon K, et al. High fat diet-induced obesity and heart dysfunction is regulated by the TOR pathway in drosophila. *Cell Metab*. 2010;12(5):533-544.

66. Figlewicz DP, Brot MD, McCall AL, Szot P. Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat: a molecular study. *Brain Res*. 1996;736(1-2):54-60.

67. Ariga H, Takahashi-Niki K, Kato I, Maita H, Niki T, Iguchi-Ariga SMM. Neuroprotective function of DJ-1 in Parkinson’s disease. *Oxid Med Cell Longev*. 2013;2013:683920.

68. Cao J, Ni J, Ma W, et al. Insight into insulin secretion from transcriptome and genetic analysis of insulin-producing cells of drosophila. *Genetics*. 2014;197(1):175-192.

69. Jain D, Jain R, Eberhard D, et al. Age-and diet-dependent requirement of DJ-1 for glucose homeostasis in mice with implications for human type 2 diabetes. *J Mol Cell Biol*. 2012;4(4):221-230.

70. Jain D, Weber G, Eberhard D, et al. DJ-1 protects pancreatic beta cells from cytokine- and streptozotocin-mediated cell death. *PLoS ONE*. 2015;10(9):e0138535.

71. Ashcroft FM, Rohm M, Clark A, Brereton MF. Is type 2 diabetes a glycogen storage disease of pancreatic β cells? *Cell Metab*. 2017;26(1):17-23.

72. Lu M, Su C, Qiao C, Bian Y, Ding J, Hu G. Metformin prevents dopaminergic neuron death in MPTP/P-induced mouse model of Parkinson’s disease via autophagy and mitochondrial ROS clearance. *Int J Neuropsychopharmacol*. 2016;19(9):pyw047.

73. Mor DE, Sohrabi S, Kaletsky R, et al. Metformin rescues Parkinson’s disease phenotypes caused by hyperactive mitochondria. *Proc Natl Acad Sci U S A*. 2020;117(42):26438-26447.

**SUPPORTING INFORMATION**

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Sanz FJ, Solana-Manrique C, Lilao-Garzón J, Brito-Casillas Y, Muñoz-Descalzo S, Paricio N. Exploring the link between Parkinson’s disease and type 2 diabetes mellitus in *Drosophila*. *The FASEB Journal*. 2022;36:e22432. doi: 10.1096/fj.202200286R